Eli Lilly’s Tirzepatide approved in the EU days after US and UK approval

November 10, 2023 10:05 AM PST | By Invezz
Follow us on Google News:

Eli Lilly (LLY) stock price movement has experienced a whirlwind since Wednesday’s approval of its diabetes medication, Tirzepatide, for chronic weight management in the United States and the United Kingdom.

The stock, took a dive on Thursday to close at $591.49 after enjoying a surge on Wednesday especially following the approval by the US FDA. On Friday, it traded in a day range of $586.00 to $596.67, displaying heightened interest in response to the expanding scope of Tirzepatide beyond its initial indication for Type 2 diabetes treatment.

EMA greenlights Tirzepatide for obesity treatment

In a significant development today, the European Medicines Agency (EMA) announced that its expert panel recommended marketing approval for Tirzepatide’s use in obesity treatment. This endorsement follows closely on the heels of the US and UK approvals, marking a crucial step in Eli Lilly’s global market strategy.

Known as Mounjaro in the EU since 2022 for Type 2 diabetes, Tirzepatide’s newfound indication reflects a growing trend in pharmaceuticals addressing both diabetes and obesity.

EMA approval fuels bullish momentum in Eli Lilly stock

Following the EMA’s favourable recommendation, Eli Lilly’s stock rose to a high of $596.67 before settling at $591.60 at press time, which was a 0.047% increase from yesterday’s close. The stock is buoyed by the positive regulatory news.

The market cap, standing at an impressive $561.42 billion USD, underscores investor confidence in the potential of Tirzepatide’s dual use. With an average volume of 3.57 million, Eli Lilly’s stock demonstrates robust liquidity, and the relatively high P/E ratio of 106.99 suggests a favorable market perception despite the drug’s monthly cost of around $1,060.

The triple Tirzepatide regulatory approvals signify a pivotal moment for the company, positioning tirzepatide as a versatile pharmaceutical option for individuals dealing with both Type 2 diabetes and obesity and it will likely shape the path for the LLY stock moving ahead.

The post Eli Lilly's Tirzepatide approved in the EU days after US and UK approval appeared first on Invezz


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Top Listed Companies